Therefore, we hypothesized that Cox-2 inhibitors might be useful to increase efficacy of anti-angiogenic drugs in experimental breast cancer by targeting a pro-angiogenic pathway distinct from VEGF inhibitors. This evidence concerns the gene PTGS2 and breast cancer.